Retatrutide: What It Is, How It Works, Uses, Side Effects, Cost

This article is part of the PlexusDx Education Hub — your resource for evidence-based guidance on GLP-1 therapies, weight management protocols, and the genetic variables that shape every metabolic decision. Browse all Peptides and GLP-1 education

"retatrutide brand name" covers a general set of questions about retatrutide: whether it has a brand name, what it is, how it works, what it is being studied for, common safety considerations, and the access landscape as of May 2026. This article provides a practical overview and links to the more specific PlexusDx Education Hub articles for deeper dives.

What Retatrutide is

Retatrutide is an investigational once-weekly triple hormone receptor agonist being developed by Eli Lilly. It is designed to activate three receptor pathways: glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon. Retatrutide does not currently have an FDA-approved brand name because it is not currently FDA-approved and is not commercially available through ordinary prescribing, telehealth, retail pharmacy, compounding pharmacy, or direct-to-consumer purchase. See the PlexusDx primer What is GLP-1? for the pathway-level background.

How it works

Retatrutide is designed to engage the body’s receptors for GIP, GLP-1, and glucagon. The GLP-1 pathway is involved in appetite, satiety, gastric emptying, and glucose regulation. The GIP pathway is another incretin pathway involved in metabolic signaling, and glucagon receptor activity may influence energy expenditure and liver-related metabolic processes. Because retatrutide is still investigational, its final brand name, dosing instructions, approved uses, contraindications, warnings, and safety profile have not been established by an FDA-approved product label.

What it is used for

Retatrutide is not currently FDA-approved for any indication, so it should not be described as being “used for” type 2 diabetes, chronic weight management, obstructive sleep apnea, or any other condition in routine clinical practice. Instead, it is being studied in clinical trials for obesity and overweight with weight-related conditions, type 2 diabetes, knee osteoarthritis pain, moderate-to-severe obstructive sleep apnea, chronic low back pain, cardiovascular and renal outcomes, and metabolic dysfunction-associated steatotic liver disease. Until approval decisions are made, legitimate access is limited to appropriate clinical-trial participation.

Common side effects

Because retatrutide is investigational, it does not yet have an FDA-approved label defining its official adverse-reaction profile, boxed warnings, contraindications, or prescribing instructions. In clinical trials of incretin-based medications, gastrointestinal symptoms such as nausea, vomiting, diarrhea, constipation, decreased appetite, and abdominal discomfort are commonly monitored. More serious safety considerations for GLP-1 and related incretin therapies can include dehydration, gallbladder problems, pancreatitis, kidney-related complications in the setting of fluid loss, and other medication-specific risks. Patients should rely on clinical-trial investigators or qualified healthcare providers for individualized safety guidance.

Cost and access

There is no legitimate standard retail price, brand-name price, insurance price, cash-pay price, or manufacturer savings-card pathway for retatrutide because it is not FDA-approved or commercially available. Any website advertising a branded version of retatrutide, compounded retatrutide, or “research” retatrutide for direct purchase should be treated as a major red flag. For FDA-approved GLP-1 and related weight-management medications, out-of-pocket cost depends on insurance coverage, approved indication, pharmacy, dose, manufacturer savings-card eligibility, and whether a regulated alternative pathway is available.

PlexusDx does not sell, distribute, or prescribe Retatrutide or any other therapeutic peptide outside its own Weight Management Protocols (which include semaglutide and tirzepatide pathways). Regardless of which GLP-1 pathway compound you and your healthcare provider eventually discuss, the underlying genetic architecture is still relevant. The Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, and 150+ genetic insights — including variants in FTO, GLP1R, and MC4R that may shape baseline GLP-1, appetite-regulation, and energy-balance biology. Knowing that profile before committing to a long-term protocol is the test before you invest approach — turning guesswork into a more informed conversation with your healthcare provider.

Related reading on PlexusDx: What Is GLP-1?, GLP-1 Receptor Agonist, GLP-1 Drugs, GLP-1 Hormone.

Disclaimer: This article is educational. PlexusDx does not sell, prescribe, or recommend dulaglutide, liraglutide, retatrutide, cagrilintide, or any other therapeutic peptide in this category beyond the semaglutide and tirzepatide products in its Weight Management Protocols. Retatrutide is investigational and is not currently FDA-approved. The Precision Peptide Genetic Test analyzes how your genes influence peptide-related biological pathways — it does not diagnose disease, determine medication eligibility, or predict response to any specific medication. Consult a qualified healthcare provider before beginning any peptide protocol.

Start upstream with the genetic context. Take the Precision Peptide Genetic Test to understand the pathway biology that applies across every GLP-1 decision.

Frequently Asked Questions

What is Retatrutide?

Retatrutide is an investigational once-weekly triple hormone receptor agonist being developed by Eli Lilly. It is designed to activate GIP, GLP-1, and glucagon receptor pathways. It is not currently FDA-approved, does not currently have an FDA-approved brand name, and is not commercially available through ordinary prescribing, telehealth, retail pharmacy, compounding pharmacy, or direct-to-consumer purchase.

How does Retatrutide work?

Retatrutide is designed to activate receptors for GIP, GLP-1, and glucagon. These pathways are involved in appetite regulation, satiety, glucose metabolism, and broader energy-balance signaling. Because retatrutide is still investigational, its final brand name, dosing instructions, approved uses, safety profile, and prescribing rules have not yet been established by an FDA-approved label.

What is Retatrutide used for?

Retatrutide is not currently FDA-approved for any use. It is being studied in clinical trials for obesity, overweight with weight-related conditions, type 2 diabetes, knee osteoarthritis pain, moderate-to-severe obstructive sleep apnea, chronic low back pain, cardiovascular and renal outcomes, and metabolic dysfunction-associated steatotic liver disease. Legitimate access is limited to appropriate clinical-trial participation.

Does genetic testing predict Retatrutide response?

No. The Precision Peptide Genetic Test does not predict response to Retatrutide or any specific medication. It analyzes pathway-level variants in FTO, GLP1R, MC4R, and TCF7L2 that may shape baseline GLP-1 and energy-balance biology — upstream context that can support a more informed conversation with a qualified healthcare provider.

This article is part of the PlexusDx Education Hub. Browse all Peptides and GLP-1 education